Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib maintenance after daratumumab + lenalidomide + dexamethasone in newly diagnosed multiple myeloma
jRCTs041260013Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM) (2 cohorts), sponsored by Takeda. Primary endpoints: Subcategorical response rate during ixazomib maintenance and Minimal residual disease (MRD)-negative rate. Started Aug 2026; status: recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs041260013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260013.